S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
S&P 500   4,526.01 (-1.12%)
DOW   34,487.88 (-0.44%)
QQQ   382.95 (-1.79%)
AAPL   162.44 (-0.81%)
MSFT   323.10 (-1.94%)
FB   305.04 (-1.72%)
GOOGL   2,824.20 (-1.23%)
AMZN   3,395.56 (-1.22%)
TSLA   1,023.75 (-5.61%)
NVDA   306.15 (-4.70%)
BABA   112.16 (-8.07%)
NIO   32.75 (-9.53%)
CGC   10.11 (-2.41%)
AMD   143.05 (-5.06%)
GE   93.06 (-2.28%)
MU   82.50 (-0.46%)
T   23.37 (+1.39%)
F   19.41 (-2.32%)
DIS   146.05 (-0.78%)
PFE   53.75 (+1.34%)
AMC   28.22 (-6.80%)
ACB   5.93 (-3.42%)
BA   197.13 (-2.59%)
NASDAQ:STOK

Stoke Therapeutics Stock Forecast, Price & News

$22.33
-1.52 (-6.37%)
(As of 12/3/2021 11:24 AM ET)
Add
Compare
Today's Range
$21.90
$25.00
50-Day Range
$22.40
$30.72
52-Week Range
$21.42
$71.58
Volume
10,492 shs
Average Volume
156,943 shs
Market Capitalization
$821.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.2
30 days | 90 days | 365 days | Advanced Chart
Receive STOK News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Stoke Therapeutics logo

About Stoke Therapeutics

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Headlines

Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7%
November 23, 2021 |  americanbankingnews.com
Stoke Therapeutics Gets JPMorgan Upgrade
November 22, 2021 |  finance.yahoo.com
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up to $27.80
November 22, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
79
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$6.46 per share

Profitability

Net Income
$-52.24 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
17,733,000
Market Cap
$821.54 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

2.52 out of 5 stars

Medical Sector

114th out of 1,391 stocks

Pharmaceutical Preparations Industry

46th out of 669 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

Is Stoke Therapeutics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Stoke Therapeutics stock.
View analyst ratings for Stoke Therapeutics
or view top-rated stocks.

How has Stoke Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STOK stock has increased by 13.2% and is now trading at $22.33.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Stoke Therapeutics?

Stoke Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,460,000 shares, an increase of 21.8% from the October 31st total of 2,020,000 shares. Based on an average daily trading volume, of 142,400 shares, the short-interest ratio is presently 17.3 days. Approximately 12.4% of the shares of the stock are short sold.
View Stoke Therapeutics' Short Interest
.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Stoke Therapeutics
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its earnings results on Monday, November, 8th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.04.
View Stoke Therapeutics' earnings history
.

What price target have analysts set for STOK?

9 Wall Street analysts have issued 12 month price targets for Stoke Therapeutics' stock. Their forecasts range from $35.00 to $76.00. On average, they expect Stoke Therapeutics' stock price to reach $57.00 in the next year. This suggests a possible upside of 155.3% from the stock's current price.
View analysts' price targets for Stoke Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.85%), Geode Capital Management LLC (0.99%), Goldman Sachs Group Inc. (0.47%), Morgan Stanley (0.39%), Voya Investment Management LLC (0.23%) and Renaissance Technologies LLC (0.23%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Robin A Walker and Stephen J Tulipano.
View institutional ownership trends for Stoke Therapeutics
.

Which institutional investors are selling Stoke Therapeutics stock?

STOK stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Morgan Stanley, Citigroup Inc., Two Sigma Investments LP, Voloridge Investment Management LLC, California State Teachers Retirement System, and Victory Capital Management Inc.. Company insiders that have sold Stoke Therapeutics company stock in the last year include Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Huw M Nash, and Stephen J Tulipano.
View insider buying and selling activity for Stoke Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Stoke Therapeutics stock?

STOK stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, HighVista Strategies LLC, Goldman Sachs Group Inc., Cowen AND Company LLC, Two Sigma Advisers LP, UBS Group AG, SG Americas Securities LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Stoke Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $22.33.

How much money does Stoke Therapeutics make?

Stoke Therapeutics has a market capitalization of $821.54 million. The company earns $-52.24 million in net income (profit) each year or ($2.09) on an earnings per share basis.

How many employees does Stoke Therapeutics have?

Stoke Therapeutics employs 79 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

Where are Stoke Therapeutics' headquarters?

Stoke Therapeutics is headquartered at 45 WIGGINS AVENUE, BEDFORD MA, 01730.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at (781) 430-8200 or via email at [email protected].


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.